Helling, Robert M.
Perenboom, Matthijs J. L.
Bauer, Prisca R.
Carpay, Johannes A.
Sander, Josemir W.
Ferrari, Michel D.
Visser, Gerhard H.
Tolner, Else A. http://orcid.org/0000-0002-6501-9971
Funding for this research was provided by:
Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie (NA)
Berta Ottenstein program University of Freiburg (NA)
Seventh Framework Programme (602633)
National Science Foundation (Brain@home 114025101)
Marvin Weil Epilepsy Research Fund (NA)
UK Epilepsy Society (NA)
Medical Delta Program (Medical Neurodelta)
Article History
Received: 8 December 2021
Accepted: 25 January 2023
First Online: 13 February 2023
Declarations
:
: JWS has been consulted by and received fees for lectures from GSK, Eisai and UCB Pharma. MDF reports grants and consultancy or industry support from Medtronic and independent support from the Netherlands Organisation for Scientific Research (NWO), NIH, European Community, and the Dutch Heart Foundation. JAC has been consulted by and received fees for lectures from Lilly, Lundbeck, Novartis, Pfizer, Teva, and UCB.
: The study was approved by Ethical Committee of Erasmus University Medical Centre, Rotterdam, and conducted according to the Declaration of Helsinki.
: All participants provided their written informed consent to participate in this study.